Rivercell is a BioTech and AI company building proprietary cell-response data infrastructure and a world model that predicts how human cells respond to treatment.
Rivercell has raised €22M across 1 funding round from 4 investors, most recently a Seed round in Oct 2026. Based in Paris, France; active in Healthtech. Data as of 7 Oct 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-10-07 | Seed | €22M |
| Alven,Bpifrance Digital Venture,HCVC,HV Capital |
| View deal → |
